Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 27, 2009

Adjuvant IL-7 Boosts Vaccine-Induced Immune Response to Tumors

  • An international team of scientists found that after a vaccine-induced immune response, interleukin-7 (IL-7) improves antitumor activities and survival in an animal model of cancer.

    The findings are published in Nature Medicine in a paper called “Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies.”

    The scientists combined IL-7 with a viral vaccine and observed that together immunity to tumors was enhanced. They found that IL-6 production increased and T helper type 17 cell differentiation was augmented.

    Furthermore, IL-7 modulated the expression of two ubiquitin ligases: Casitas B-lineage lymphoma b (Cbl-b), a negative regulator of T-cell activation, was repressed, and SMAD-specific E3 ubiquitin protein ligase-2 (Smurf2) was enhanced, which antagonizes transforming growth-factor signaling.

    The scientists also explain that while short-term IL-7 therapy potently enhanced vaccine-mediated immunity, in the absence of vaccination it is inefficient in promoting antitumor immune responses, despite inducing homeostatic proliferation of T cells.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »